期刊文献+

基于Armored RNA的BCR-ABL融合基因质控物研制

Development of quality control substance for BCR-ABL fusion gene based on Armored RNA
下载PDF
导出
摘要 目的制备以MS2噬菌体装甲RNA(Armored RNA)为材料的BCR-ABL融合基因质控物。方法获取临床p210型BCR-ABL融合基因骨髓标本cDNA,PCR扩增p210型BCR-ABL融合基因片段和ABL内参基因片段。将MS2噬菌体成熟蛋白基因和衣壳蛋白基因克隆于pACYCDuet-1,制成pACYC-MS2,然后将p210型BCR-ABL融合基因和ABL内参基因分别插入pACYC-MS2载体,经原核表达、分子筛纯化、反转录-PCR鉴定后分别制成包装有p210型BCR-ABL融合基因和ABL内参基因片段的病毒样颗粒(VLPs)。进行稳定性、均一性检测,同时判断质控物的适用性。结果成功制备了包装有p210型BCR-ABL融合基因和ABL内参基因的VLPs质控物。均一性检测表明质控物目的片段拷贝数水平是均一的。稳定性检测显示质控物标本在-20℃可至少稳定保存7个月,4℃稳定保存3个月,室温稳定保存15 d,37℃稳定保存1周。用实时荧光定量PCR试剂盒检测质控物水平,pACYC-MS2-p210 VLPs和pACYC-MS2-ABL VLPs标准曲线的R2分别为0.9940和0.9917,具有很好的适用性。结论将Armored RNA作为材料所制备的BCR-ABL融合基因质控物稳定性、均一性较好,适用于评价BCR-ABL融合基因检测试剂盒的性能,具有广泛的应用前景。 Objective To prepare BCR-ABL fusion gene quality control substance using MS2 phage Armored RNA as material.Methods obtained the cDNA of clinical bone marrow samples of p210 type BCRABL fusion gene,and amplified BCR-ABL fusion gene fragment and ABL reference gene fragment by PCR.The mature protein gene and capsid protein gene of MS2 phage were cloned into pACYCDuet-1 to prepare pACYC-MS2,then,the p210 type BCR-ABL fusion gene and ABL reference gene were inserted into the vector pACYC-MS2 respectively.After prokaryotic expression,molecular sieve purification and reverse transcription-PCR identification,virus-like particles(VLPs)packaged with p210 type BCR-ABL fusion gene and ABL reference gene fragments were prepared.The stability and homogeneity were detected,and the applicability of quality control materials was evaluated.Results The VLPs packaged p210 type BCR-ABL fusion gene and ABL reference gene were successfully prepared.The homogeneity test showed that the copy number level of the target fragment was uniform.The stability test showed that the quality control substance could be stored stably for at least 7 months at-20℃,3 months at 4℃,15 days at room temperature and 1 week at 37℃.Quantitative real-time PCR kit was used to detect the level of the quality control substance,and the R2 of the standard curves of pACYC-MS2-p210 VLPs and pACYC-MS2-ABL VLPs were 0.9940 and 0.9917 respectively,with good applicability.Conclusion The BCR-ABL fusion gene quality control substance prepared by Armored RNA has good stability and homogeneity,which can be used to evaluate the performance of BCR-ABL fusion gene detection kit,and has a wide application prospect.
作者 李建英 毛玉环 刘珊玲 LI Jianying;MAO Yuhuan;LIU Shanling(Department of Clinical Laboratory,the First Hospital of Changsha,Changsha,Hunan 410005,China)
出处 《检验医学与临床》 CAS 2020年第24期3588-3592,共5页 Laboratory Medicine and Clinic
关键词 BCR-ABL融合基因 装甲RNA 质控物 性能评价 BCR-ABL fusion gene Armored RNA quality control substance performance assessment
  • 相关文献

参考文献4

二级参考文献18

  • 1邢秀华,王雷,王松酶,徐克惠,于向民.白血病bcr/abl mRNA的荧光定量RTP-CR检测[J].青岛大学医学院学报,2004,40(2):139-141. 被引量:7
  • 2林江,钱军,陈子兴,薛永权,张永宁,费霞,江云伟.应用实时定量PCR检测慢性粒细胞白血病bcr/abl^(p190)融合基因转录本[J].中华血液学杂志,2005,26(5):307-308. 被引量:3
  • 3邓明凤,王昌富,张万胜,李琳芸,彭长华,陈永玲.慢性髓细胞白血病患者染色体分析及bcr/abl融合基因转录本定量的临床意义[J].临床检验杂志,2006,24(3):179-181. 被引量:5
  • 4van Rhee F,Hochhaus A,Lin F. p190 BCR-ABL mRNA is expressed at low levels in p210-positive chronic myeloid and acute lymphoblastic leukemias[J].Blood,1996,(12):5213.
  • 5Lichty BD,Keating A,Callum J. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia[J].British Journal of Haematology,1998,(03):711.doi:10.1046/j.1365-2141.1998.01033.x.
  • 6Arana-Trejo RM,Ruiz Sanchez E,Ignacio-Ibarra G. BCR/ABL p210,p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML)[J].Clinical and Laboratory Haematology,2002,(03):145.doi:10.1046/j.1365-2257.2002.00413.x.
  • 7Agirre X,Román-G6mez J,Vázquez I. Coexistence of different clonal populations harboring the b3a2 (p210) and e1 a2 (p190)BCR-ABL1 fusion transcripts in chronic myelogenous leukemia resistant to imatinib[J].Cancer Genetics and Cytogenetics,2005,(01):22-26.
  • 8张之南;沈悌.血液病诊断及疗效标准[M]北京:北京科学技术出版社,2007134-135.
  • 9Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia[J].Nature Reviews Cancer,2005,(03):172.doi:10.1038/nrc1567.
  • 10Elmaagacli AH,Beelen DW,Opalka B. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage[J].Annals of Hematology,2000,(08):424.doi:10.1007/s002770000169.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部